Coya Therapeutics Q3 R&D expenses more than double due to trial advancement
COYA•Coya Therapeutics reported a $10.60 million Q3 net loss as R&D expenses more than doubled year over year, mainly due to advancement of its COYA 302 ALS trial. The company completed enrollment in the Phase 2/3 ALSTARS trial and expects topline data in early Q2 2027.
1. Trial costs rise
Coya Therapeutics’ third-quarter R&D expenses more than doubled year over year, mainly because of increased preclinical and clinical costs for its COYA 302 ALS Phase 2/3 trial. Collaboration revenue fell sharply due to the absence of license revenue recognized in the prior-year period, and the company reported a $10.60 million net loss.
2. ALS trial outlook
The company completed enrollment in the Phase 2/3 ALSTARS trial for ALS and expects topline data in early Q2 2027. Coya plans to initiate a Phase 2 study of COYA 302 in FTD in 2027 and expects its current cash to fund operations into the second half of 2027.
Related News
Alliance Entertainment partners with JAKKS Pacific to distribute anime, VTuber products in North America outside mass retail
UiPath partners with Google Cloud on Gemini for healthcare automation
